75 results
6-K
EX-5.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
.
2Assumptions
In giving this opinion we have relied upon the assumptions set forth in this paragraph 2 without having carried out any independent
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
shall cause (1) the Company’s auditors (the “Accountants”), or other independent accountants satisfactory to the Manager forthwith to furnish … satisfactory to the Manager, confirming that they are independent accountants within the meaning of the Act and the Exchange Act and the respective
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.
Exemption from … the requirements that director nominees are selected, or recommended for selection by our board of directors, either by (i) independent directors
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
Biolabs Limited and the remaining 4.35% by independent third-party shareholders.
Logico Bioproduct Corp. (“Logico BVI”) — Logico Bioproducts Corp … at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Current report (foreign)
4:06pm
with the Articles;
Independent Director means a Director who is an independent director as defined in the Designated Stock Exchange Rules as determined … .
14.8 For so long as Shares are listed on a Designated Stock Exchange, the Directors shall include at least such number of Independent Directors
424B3
3d1xj7 tz92lkj7
20 Dec 23
Prospectus supplement
4:03pm
F-3
vj3n2
5 Dec 23
Shelf registration (foreign)
4:06pm
F-3
EX-23.2
0p79 h8x1uqviwbn
5 Dec 23
Shelf registration (foreign)
4:06pm
F-3
EX-23.1
0ygf p1a6mlcctbayiel
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.4
aurcorv81lb55qjmar
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.1
0u21m4eqqu2ypslnn9
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
qs187
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-4.1
4qo0w10yy
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
3rh248c7ybng
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
18pm91n85tr8
21 Apr 23
Current report (foreign)
4:30pm
424B3
qf6hho
31 Mar 23
Prospectus supplement
4:04pm
424B3
8ow nh7zz
2 Dec 22
Prospectus supplement
4:17pm
F-1
EX-23.1
slmar12wduoew
18 Nov 22
Registration statement (foreign)
5:39pm